Reply #10: There is disagreement over "standard" treatment for this disease. The watchful waiting

[TooBigaTent]

approach is, in many cases, the better option. The problem is, it is impossible to tell any specific man whether it is the right decision for him.

Eventually, genetic research will be able to determine whether the cancer is slow-growing or aggressive. Until that point, insurance companies will always take the cheaper way out. Thus, they will not pay for what they consider "experimental" or "unsubstantiated" care. It all comes down to the numbers - dollars and age.